These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1578493)

  • 1. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
    Wissner A; Carroll ML; Green KE; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Wrenn S; Kohler CA
    J Med Chem; 1992 May; 35(9):1650-62. PubMed ID: 1578493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF.
    Wissner A; Carroll ML; Johnson BD; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Trova MP; Kohler CA
    J Med Chem; 1992 Dec; 35(26):4779-89. PubMed ID: 1336052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
    Trova MP; Wissner A; Carroll ML; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Kohler CA
    J Med Chem; 1993 Mar; 36(5):580-90. PubMed ID: 8496938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
    Takatani M; Yoshioka Y; Tasaka A; Terashita Z; Imura Y; Nishikawa K; Tsushima S
    J Med Chem; 1989 Jan; 32(1):56-64. PubMed ID: 2909744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists.
    Tokumura A; Yoshida J; Okasaka N; Fukuzawa K; Tsukatani H
    Thromb Res; 1987 Apr; 46(1):153-61. PubMed ID: 3590110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel class of platelet activating factor (PAF) antagonists. II. Modification of the 2-position of the glycerol backbone of PAF-sulfonamide isosteres.
    Tsuri T; Matsui T; Haga N; Kamata S; Hagishita S; Takahashi K; Kakushi H; Uchida K; Hatakeyama H; Kurosawa A
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):85-95. PubMed ID: 1576692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH
    J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets.
    Hofmann B; Ostermann G; Kertscher HP; Till U
    Thromb Res; 1988 Feb; 49(4):415-23. PubMed ID: 3381200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
    Grigoriadis G; Stewart AG
    Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.
    Ostermann G; Hofmann B; Kertscher HP; Till U
    Thromb Res; 1991 Feb; 61(3):261-9. PubMed ID: 2028445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
    Lamouri A; Heymans F; Tavet F; Dive G; Batt JP; Blavet N; Braquet P; Godfroid JJ
    J Med Chem; 1993 Apr; 36(8):990-1000. PubMed ID: 8478911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
    J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
    Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP
    J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships for platelet-activating factor (PAF) and analogues reveal differences between PAF receptors on platelets and macrophages.
    Stewart AG; Grigoriadis G
    J Lipid Mediat; 1991 Nov; 4(3):299-308. PubMed ID: 1662547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
    Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
    J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.